HomeIngredientConstruction and characterization of Juglans regia L. polyphenols nanoparticles based on bovine serum albumin and Hohenbuehelia serotina polysaccharides, and their gastrointestinal digestion and colonic fermentation in vitro

Construction and characterization of Juglans regia L. polyphenols nanoparticles based on bovine serum albumin and Hohenbuehelia serotina polysaccharides, and their gastrointestinal digestion and colonic fermentation in vitro

January 14, 2022

Food Funct. 2021 Nov 1;12(21):10397-10410. doi: 10.1039/d1fo01993g.

ABSTRACT

Herein, we report the construction and characterization of nanoparticles based on bovine serum albumin and Hohenbuehelia serotina polysaccharides for the delivery of polyphenols isolated from the shells of Juglans regia L. (BSA-JRP-HSP NPs). We also systematically investigated their gastrointestinal digestion and colonic fermentation characteristics in vitro. BSA-JRP-HSP NPs, with amorphous properties and regular spherical morphological features, have a high encapsulation efficiency of 88.47 ± 0.04%, average particle size of 285.7 ± 3.1 nm, and zeta potential of -12.20 ± 0.61 mV, and they exhibit excellent photothermal stabilities and strong mucin adhesion capacity. Through measurements of gastrointestinal digestion and colonic fermentation in vitro, the results suggest that BSA-JRP-HSP NPs presented well-sustained release characteristics for preventing the biodegradation of JRP during gastrointestinal digestion. After gastrointestinal digestion, BSA-JRP-HSP NPs could modulate the composition and structure of gut microbiota, promoting the growth of beneficial bacterial (e.g. Prevotella, Dialister, Akkermansia, etc.) and inhibiting the growth of pathogenic bacteria (e.g. Bacteroides, Phascolarctobacterium, Lachnospiracea incertae sedis, etc.). The production of short-chain fatty acids (SCFAs) including acetic acid, propionic acid, and butyric acid was remarkably enhanced by treatment with BSA-JRP-HSP NPs. This study has proved that BSA-JRP-HSP NPs can serve as a novel candidate for improving the bioavailability of JRP.

PMID:34554172 | DOI:10.1039/d1fo01993g

Related Posts

About The Author

Patrick Blanchard MD

Meet Dr. Blanchard Dr. Blanchard’s medical practice is an embodiment of Integrative health which brings conventional and complementary approaches together in a coordinated way. Conveniently located in sunny Florida and over the internet with ValiseMD’s secure HIPPA compliant telXmed servers. Since 1994, patients with a wide range of challenging medical problems have achieved optimum health using the best of natural medicine, judiciously combined with high-tech innovations. Breakthroughs are often achieved even after patients have consulted mainstream specialists and holistic practitioners. Dr. Blanchard is founder and CEO of ValiseMD, Inc. He is board certified in Family Medicine since 1994 and awarded Fellow of the American Academy of Family Physicians in 2001. He received the ‘Teacher of the Year’ award from the University of Kansas School of Medicine at completion of his residency in Family Medicine. He completed a fellowship at Wake Forest University in the field of vascular neurosonology. He holds a medical patent in the field of Gastroenterology. He holds an unrestricted license to practice medicine and surgery in Florida. He started his medical career as a Emergency Medical Technician, then as a Paramedic and later a Medical Doctor.